Evoke Pharma Valuation
| EVOK Stock | USD 30.15 0.45 1.52% |
At this time, the firm appears to be overvalued. Evoke Pharma shows a prevailing Real Value of $24.38 per share. The current price of the firm is $30.15. Our model computes the value of Evoke Pharma from reviewing the firm fundamentals such as Profit Margin of (0.36) %, current valuation of 12.48 M, and Shares Outstanding of 1.72 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Evoke Pharma's valuation include:
Price Book 5.6351 | Enterprise Value | Enterprise Value Ebitda (0.36) | Price Sales 1.3135 | Enterprise Value Revenue 0.8654 |
Overvalued
Today
Please note that Evoke Pharma's price fluctuation is slightly risky at this time. Calculation of the real value of Evoke Pharma is based on 3 months time horizon. Increasing Evoke Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Evoke Pharma's intrinsic value may or may not be the same as its current market price of 30.15, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 30.15 | Real 24.38 | Target 18.0 | Hype 29.29 | Naive 29.67 |
The intrinsic value of Evoke Pharma's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Evoke Pharma's stock price.
Estimating the potential upside or downside of Evoke Pharma helps investors to forecast how Evoke stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Evoke Pharma more accurately as focusing exclusively on Evoke Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Evoke Pharma's intrinsic value based on its ongoing forecasts of Evoke Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Evoke Pharma's closest peers.
Evoke Pharma Cash |
|
Evoke Pharma Total Value Analysis
Evoke Pharma is currently estimated to have valuation of 12.48 M with market capitalization of 18.95 M, debt of 5.16 M, and cash on hands of 13.45 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Evoke Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
12.48 M | 18.95 M | 5.16 M | 13.45 M |
Evoke Pharma Investor Information
About 25.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.38. Evoke Pharma had not issued any dividends in recent years. The entity had 1:12 split on the 1st of August 2024. Based on the key measurements obtained from Evoke Pharma's financial statements, Evoke Pharma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Evoke Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Evoke Pharma has an asset utilization ratio of 58.5 percent. This suggests that the Company is making $0.59 for each dollar of assets. An increasing asset utilization means that Evoke Pharma is more efficient with each dollar of assets it utilizes for everyday operations.Evoke Pharma Profitability Analysis
Based on the key profitability measurements obtained from Evoke Pharma's financial statements, Evoke Pharma may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Evoke Pharma's ability to earn profits and add value for shareholders.Net Loss | First Reported 2011-12-31 | Previous Quarter -1.6 M | Current Value -1.2 M | Quarterly Volatility 1.3 M |
For Evoke Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Evoke Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Evoke Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Evoke Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Evoke Pharma over time as well as its relative position and ranking within its peers.
Evoke Pharma Earnings per Share Projection vs Actual
The next projected EPS of Evoke Pharma is estimated to be -0.47 with future projections ranging from a low of -0.47 to a high of -0.47. Evoke Pharma's most recent 12-month trailing earnings per share (EPS TTM) is at -1.38. Please be aware that the consensus of earnings estimates for Evoke Pharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Evoke Pharma Earnings Estimation Breakdown
The calculation of Evoke Pharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Evoke Pharma is estimated to be -0.47 with the future projection ranging from a low of -0.47 to a high of -0.47. Please be aware that this consensus of annual earnings estimates for Evoke Pharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.47 Lowest | Expected EPS | -0.47 Highest |
Evoke Pharma Earnings Projection Consensus
Suppose the current estimates of Evoke Pharma's value are higher than the current market price of the Evoke Pharma stock. In this case, investors may conclude that Evoke Pharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Evoke Pharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 3 | 75.72% | -0.45 | -0.47 | -1.38 |
Evoke Pharma Ownership Allocation
The market capitalization of Evoke Pharma is $18.95 Million. Evoke Pharma shows 10.62 percent of its outstanding shares held by insiders and 25.05 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Evoke Pharma Profitability Analysis
The company reported the previous year's revenue of 10.25 M. Net Loss for the year was (5.35 M) with profit before overhead, payroll, taxes, and interest of 13.99 M.About Evoke Pharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Evoke Pharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Evoke Pharma based exclusively on its fundamental and basic technical indicators. By analyzing Evoke Pharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Evoke Pharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Evoke Pharma. We calculate exposure to Evoke Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Evoke Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 11.4 M | 11.9 M | |
| Pretax Profit Margin | (0.47) | (0.49) | |
| Operating Profit Margin | (0.46) | (0.48) | |
| Net Loss | (0.47) | (0.49) | |
| Gross Profit Margin | 0.87 | 0.91 |
Evoke Pharma Current Valuation Indicators
Evoke Pharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Evoke Pharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Evoke Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Evoke Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Evoke Pharma's worth.When determining whether Evoke Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Evoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Evoke Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Evoke Pharma Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. Projected growth potential of Evoke fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Evoke Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.38) | Revenue Per Share | Quarterly Revenue Growth 0.614 | Return On Assets | Return On Equity |
Investors evaluate Evoke Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Evoke Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Evoke Pharma's market price to deviate significantly from intrinsic value.
It's important to distinguish between Evoke Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evoke Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Evoke Pharma's market price signifies the transaction level at which participants voluntarily complete trades.